Please login to the form below

Not currently logged in

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults
Boehringer Ingelheim

Boehringer and Lilly's Jardiance (empagliflozin) has been backed by NICE as a treatment for type 2 diabetes.

The positive final appraisal decision from NICE marks a turnaround for the product, which was last year knocked back by the cost-effectiveness body for England and Wales.

In draft guidance issued in August NICE acknowledged the drug's clinical effectiveness but took issue with what it saw as a lack of data to justify Jardiance's cost.

Boehringer and Lilly said the drug has been recommended for a number of indications in type 2 diabetes, including in combination with metformin and in a triple therapy regimen in combination with metformin and a sulfonylurea.

Jardiance was also recommended for type 2 diabetes patients with metformin and a thiazolidinedione and in combination with insulin with or without other antidiabetic drug and in those who are currently receiving NHS treatment.

Dr Charlies De Wet, medical director at Boehringer Ingelheim, said: “We are very pleased that NICE has recommended empagliflozin as a clinically and cost effective treatment. It will provide an additional therapeutic option for the management of glycaemic control in people with type 2 diabetes in England.”

Jardiance (empagliflozin) is jointly marketed by Boehringer and Eli Lilly and forms part of their 2011 diabetes alliance. Approved in Europe in May last year, the drug received a US licence in August.

Article by
Kirstie Pickering

26th January 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...